UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~April 98, 2015

SELECT MEDICAL HOLDINGS CORPORATION
SELECT MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware Delaware		001-34465 001-31441		20-1764048 23-2872718
(State or other jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of principal executive offices) (Zip Code)

(717) 972-1100

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

~~Attached~~On ~~as Exhibit~~April ~~99.1~~8, ~~and~~2015, ~~furnished~~MJ ~~for~~Acquisition ~~purposes~~Corporation, ~~of Regulation FD is~~ a ~~press~~joint ~~release~~venture ~~issued~~that by Select Medical ~~Holdings~~ Corporation (the “Company”) onhas ~~January~~created with Welsh, Carson, Anderson 9& Stowe XII, ~~2015~~L.P., ~~announcing~~launched a financing transaction intended to provide debt financing to fund a portion of the ~~Company~~purchase price for its previously announced acquisition of Concentra Inc. (“Concentra”). The purchase price for Concentra of $1.055 billion represents approximately 8.3 times Concentra’s ~~business~~2014 ~~outlook~~Adjusted ~~for~~EBITDA ~~calendar~~after ~~year~~giving ~~2015~~effect to expected synergies. MJ Acquisition Corporation is expecting to raise approximately $650 million of debt financing.

~~Attached~~The asinformation ~~Exhibit~~in this Current Report on Form ~~99.2~~8-K ~~and~~is being furnished ~~for~~solely ~~purposes~~to satisfy the requirements of Regulation FD isand ashall ~~presentation~~not be deemed to be ~~given~~“filed” byfor ~~Select~~purposes ~~Medical~~of ~~Holdings~~Section 18 ~~Corporation~~of onthe ~~Monday,~~Securities ~~January 12~~Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, ~~2015~~nor atshall it be deemed to be incorporated by reference in any filing under the ~~33rd~~Securities ~~Annual~~Act ~~J.P.~~of ~~Morgan~~1933 ~~Healthcare~~or ~~Conference~~the Exchange Act.

~~The~~Cautionary ~~information~~Note inRegarding ~~this Current Report on Form 8~~Forward-KLooking (including Exhibit 99.1 and 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.Statements

~~Item~~Except 9for historical information, all other information in this Form 8-K consists of forward-looking statements.01 ~~Financial~~These forward-looking statements involve a number of risks, uncertainties and other factors, including the expected synergies which may result from the proposed acquisition of Concentra by MJ Acquisition Corporation, which may cause the actual results to be materially different from those expressed or implied in the forward-looking statements. There can be no assurance that the financing referenced above will be completed as described herein or at all. Other important factors are discussed under the caption “Forward-Looking Statements” in the Company’s Form 10-K Annual Report for the year ended December 31, 2014 and ~~Exhibits~~in subsequent filings made prior to or after the date hereof. The Company does not intend to review or revise any particular forward-looking statement in light of future events.

~~(d) Exhibits.~~2

Exhibit Number		Description
99.1		Press Release, dated January 9, 2015, announcing Select Medical Holdings Corporation’s business outlook for 2015.
99.2		Select Medical Holdings Corporation Presentation.

SIGNATURE

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.

SIGNATURE

	SELECT MEDICAL HOLDINGS CORPORATION
	SELECT MEDICAL CORPORATION


Date: April 8, 2015	By:	/s/ Michael E. Tarvin
		Michael E. Tarvin
		Executive Vice President, General Counsel and Secretary

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.~~3

	SELECT MEDICAL HOLDINGS CORPORATION
	SELECT MEDICAL CORPORATION
Date: January 12, 2015	By:	/s/ Michael E. Tarvin
		Michael E. Tarvin
		Executive Vice President, General Counsel and Secretary

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release, dated January 9, 2015, announcing Select Medical Holdings Corporation’s business outlook for 2015.
99.2		Select Medical Holdings Corporation Presentation.

Filing Compare · SELECT MEDICAL CORP